AC Nordic ApS purchased $40K of NORD
AC Nordic ApS purchased 20,000 shares of Nordicus Partners Corp (NORD) at $2.00 on 2026-07-08.
Nordicus Partners Corp
Nordicus Partners is a U.S. publicly listed biotechnology company that acquires and develops drugs from early-stage life sciences companies in the Nordic region. It focuses on therapeutics for diseases with unmet medical needs, with a scientific focus on inflammation and immune modulation. Its portfolio includes Orocidin, which develops QR-01 for periodontitis; Bio-Convert, which develops QR-02 for oral leukoplakia; and NoviThera, which develops QR-04, a monoclonal antibody treatment for psoriasis. Nordicus scouts companies, offers selected businesses an accelerator program with capital, resources and advice, and typically seeks to acquire them after milestones are met. It aims to develop portfolio drugs through Phase I, then may pursue a sale or merger, further development, a pharmaceutical partnership or a standalone IPO. Nordicus is headquartered in Beverly Hills, California.
No enriched coverage for $NORD in the last 7 days.
No SEC Form 4 filings for $NORD in the last 30 days.
See all $NORD insider activity →AC Nordic ApS purchased 20,000 shares of Nordicus Partners Corp (NORD) at $2.00 on 2026-07-08.
Nordicus Partners raised $1 million by issuing four $300,000 convertible notes to investors, each with 5% interest and maturing in 2027. Investors received commitment shares, with conversion allowed after 2027 or in default, at 90% of the 10-day average price. The company agreed to register conversion shares for resale, according to an SEC filing.
Nordicus Partners amended CEO Henrik Rouf's employment agreement, extending it to 2027 and granting 2M share options. CFO Bennett J. Yankowitz also received a new agreement and 1M share options, both effective November 5, 2026, with a $3.25 exercise price and 10-year terms.
Recent NORD coverage spans corporate actions and insider activity.
Small insider purchase may signal confidence but limited price impact due to modest size.
Small-cap financing likely adds modest dilution risk and modest pressure on the stock.
Executive compensation changes are unlikely to move the stock materially.
The convertible notes create potential dilution and modest debt, likely exerting slight downward pressure on the stock.
The small private raise adds dilution but is unlikely to move the stock materially.
AlphAI scores every news story that mentions NORD with an AI model for sentiment and relevance, and aggregates insider trades from Nordicus Partners Corp's SEC EDGAR Form 4 filings. Figures refresh continuously.
AC Nordic ApS purchased 20,000 shares of Nordicus Partners Corp (NORD) at $2.00 on 2026-07-08.
Nordicus Partners raised $1 million by issuing four $300,000 convertible notes to investors, each with 5% interest and maturing in 2027. Investors received commitment shares, with conversion allowed after 2027 or in default, at 90% of the 10-day average price. The company agreed to register conversion shares for resale, according to an SEC filing.
Nordicus Partners amended CEO Henrik Rouf's employment agreement, extending it to 2027 and granting 2M share options. CFO Bennett J. Yankowitz also received a new agreement and 1M share options, both effective November 5, 2026, with a $3.25 exercise price and 10-year terms.
Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On November 5, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to Keystone Capital Partners LLC (“Keystone”), Seven Knots, LLC, 5T Capital Partners, LP and Creo Investments LLC (collectively, the “ Investors
Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Unregistered Sales of Equity Securities. Item 3.02. Unregistered Sales of Equity Securities. In July and October 2026, we received subscription commitments from two private investors for a total of 40,000 restricted shares of our common stock, par value $0.001 per share. The price per share was $2.00. The proceeds to us
Nordicus Partners Corporation (OTCQB: NORD), a biotech firm focused on oral disorder treatments, announced its shares will start trading on the Nasdaq Capital Market on October 30, 2026, under the same ticker symbol, NORD. The company acquires and develops drugs from Nordic biotech firms, with recent acquisitions including Orocidin A/S and Bio-Convert A/S.
Nordicus Partners issued a $147,000 demand promissory note to ABCHill Holding at 6% interest. The note is payable on demand and can be prepaid without penalty. The lender is linked to a Nordicus director. The agreement aims to improve the company's near-term liquidity, according to an SEC filing.
Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 15, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to ABCHill Holding ApS (the “Lender”) a Promissory Note (the “Note”) in the principal amount of $147,000. The Note is payable on demand and bear
Nordicus Partners issued a $75,000 demand note to AC Nordic, controlled by director Torben Jensen, for working capital and corporate purposes. The note has a 6% interest rate and is payable on demand. The transaction was approved by disinterested board members, with Jensen abstaining.
Nordicus Partners Corp (NORD) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. On October 8, 2026, Nordicus Partners Corporation (“we” or the “Company”) issued to AC Nordic ApS (the “Lender”) a Promissory Note (the “Note”) in the principal amount of $75,000. The Note is payable on demand and bears intere